RxDoctor Payments Data

Nazila Biria, MD

Internal Medicine · Scottsdale, AZNPI 1114986379

Payments from drug & device makers

$17,845in general payments, 2019–2025

Across 1,260 payments — averaging $14.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • Novo Nordisk$3K
  • AbbVie$3K
  • GSK$684
  • Merck$563
  • Johnson & Johnson$500
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$17,75099%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)278$3,910
Novo Nordisk316$2,829
AbbVie(2 entities)178$2,667
GSK38$684
Merck41$563
Johnson & Johnson(2 entities)29$500
Pfizer31$478
Lilly USA, LLC25$426
Boehringer Ingelheim26$390
Takeda Pharmaceuticals U.S.A., Inc.21$361
Kowa Pharmaceuticals America, Inc.22$305
Boston Scientific5$291
Phathom Pharmaceuticals, Inc.11$259
AstraZeneca(2 entities)16$241
Medtronic4$235
Astellas Pharma US Inc10$234
Madrigal Pharmaceuticals6$213
Harmony Biosciences LLC12$175
Endo Pharmaceuticals Inc.12$169
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC12$168
Otsuka America Pharmaceutical, Inc.7$140
Eisai Inc.9$131
Exact Sciences5$129
Jazz Pharmaceuticals Inc.9$127
Sanofi-aventis U.S. LLC7$115
Ironwood Pharmaceuticals, Inc7$100
Esperion Therapeutics, Inc.6$99
Novartis6$98
Xeris Pharmaceuticals, Inc.6$95
Redhill Biopharma Inc.7$92
Corcept Therapeutics4$90
Amarin Pharma, Inc.6$83
QOL Medical, LLC5$75
Gilead5$70
Bausch Health US, LLC4$67
Sumitomo Pharma America, Inc.4$67
Tolmar, Inc.4$66
Bayer3$63
Biohaven Pharmaceutical Holding Company Ltd.4$61
Insulet Corporation3$58
Braintree Laboratories, Inc.3$53
Arbor Pharmaceuticals, Inc.1$52
Lundbeck LLC3$50
Abbott3$50
Idorsia Pharmaceuticals US Inc3$47
Philips North America LLC2$44
Teva Pharmaceuticals USA, Inc.3$42
Currax Pharmaceuticals LLC3$37
Aerin Medical Inc.1$32
Celltrion USA Inc.2$30
Avion Pharmaceuticals2$29
Mannkind Corporation2$28
Amneal Pharmaceuticals LLC2$26
Shire North American Group Inc2$25
Trilliant Surgical LLC.1$22
Ferring Pharmaceuticals Inc.1$20
Inspire Medical Systems, Inc.1$19
ANI Pharmaceuticals, Inc.1$18
Lexicon Pharmaceuticals, Inc.1$17
Mayne Pharma Commercial LLC1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,845 in reported general payments places this provider in the 95th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$249,912
Medicare patients
473
Services billed
5,675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$139,161
JardianceEmpagliflozin67$77,742
MounjaroTirzepatide58$66,393
EliquisApixaban52$49,803
Repatha SureclickEvolocumab50$39,478
FarxigaDapagliflozin Propanediol35$26,661
JanuviaSitagliptin Phosphate35$25,516
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$22,620
WegovySemaglutide15$21,332
MyrbetriqMirabegron27$20,270
GemtesaVibegron25$19,785
XareltoRivaroxaban14$18,373
Breo ElliptaFluticasone/Vilanterol37$17,230
RybelsusSemaglutide15$16,127
JanumetSitagliptin Phos/Metformin Hcl18$14,240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy, Rybelsus$2,829$176,620132 claims
Boehringer IngelheimJardiance$390$77,74267 claims
Lilly USA, LLCMounjaro$426$66,39358 claims
MerckJanuvia, Janumet, Janumet Xr$563$51,68468 claims
PfizerEliquis$478$49,80352 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$684$46,32483 claims
AstraZenecaFarxiga$241$26,66135 claims
Astellas Pharma US IncMyrbetriq$234$20,27027 claims
Sumitomo Pharma America, Inc.Gemtesa$67$19,78525 claims
Johnson & JohnsonXarelto$500$18,37314 claims
AbbVieSynthroid$2,667$4,66360 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$26$3,403300 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →